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Background: The CYP2D6 enzyme is involved in the metabolism of numerous
psychopharmacological drugs. Guidelines recommend how to adjust the dose of
medication based on the CYP2D6 genotype.
Aims: To evaluate the effect of dose adjustment to the CYP2D6 genotype
and phenotype, in patients with severe mental illness (SMI) already receiving
psychopharmacological treatment.
Methods: A total of 269 psychiatric patients (on the island Curaçao) receiving
antipsychotic treatment were genotyped for CYP2D6. Of these, 45 patients were
included for dose adjustment according to the clinical guideline of the Royal Dutch
Association for the Advancement of Pharmacy, i.e., 17 CYP2D6 poor metabolizers,
26 intermediate metabolizers, and 2 ultrarapid metabolizers. These 45 patients were
matched for age, gender, and type of medication with a control group of 41 patients who
were CYP2D6 extensive metabolizers (i.e., with a normal CYP2D6 function). At baseline
and at 4 months after dose adjustment, subjective experience, psychopathology,
extrapyramidal side-effects, quality of life, and global functioning were assessed in these
two groups.
Results: At baseline, there were no differences between the groups regarding the
prescribed dosage of antipsychotics, the number of side-effects, psychiatric symptoms,
global functioning, or quality of life. After dose adjustment, no significant improvement in
these parameters was reported.
Conclusion: In psychiatric patients with SMI already receiving antipsychotic treatment,
dose adjustment to the CYP2D6 genotype or phenotype according to the guidelines
showed no beneficial effect. This suggests that dose adjustment guidelines are currently
not applicable for patients already using antipsychotics.
ClinicalTrials.gov: Cost-effectiveness of CYP2D6 and CYP2C19 Genotyping in
Psychiatric Patients in Curacao; Identifier: NCT02713672; https://clinicaltrials.gov/ct2/
show/NCT02713672?term=CYP2D6&rank=5
Keywords: CYP2D6, severe mental illness (SMI), guidelines, dose adjustment, genotyping, psychopharmacology,
personalized medicine
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INTRODUCTION
The cytochrome P450 isozymes, in particular CYP2D6,
is responsible for the biotransformation of many
psychopharmacological drugs (1, 2). Substrates of CYP2D6
include first generation antipsychotics, selective serotonin
receptor inhibitors and tricyclic antidepressants1. Based on
genetic variation, patients can be divided into poor metabolizers
(PM), intermediate metabolizers (IM), extensive metabolizers
(EM), and ultrarapid metabolizers (UM). The recommended
dosages of psychopharmacological medication that are
metabolized by this enzyme are based on the metabolism
of the most common genotype, i.e., the EM type (i.e., a normal
CYP2D6 function). However, because the plasma level of a drug
is related to the genotype, the same dosage will probably lead
to a higher plasma level in PMs and IMs, as compared to EMs,
and to a lower plasma level in UMs as compared to EMs. The
plasma level is often related to the effectiveness of the drug and
the risk of dose-related side-effects (3–7). Also, when physicians
prescribe a drug metabolized by CYP2D6 without taking into
account the genotype, the hospital stay is longer (and the costs
higher) in patients with a PM and UM profile (8).
Clinical guidelines recommend dose adjustment according to
the CYP2D6 genotype (9–11). However, the current guidelines
do not differentiate between patients that start vs. those that
are already receiving psychopharmacological treatment. Patients
with severe mental illness (SMI) are especially known to suffer
from problems with adverse drug reactions, lack of medication
effect, and new models of care are warranted (12–16). In a study
in patients with SMI, more adverse drug events and higher costs
were found in the extreme metabolizer groups (17). In a cost
analysis study it was found that genotyping in patients with
schizophrenia could lead to lower treatment costs (18).
Genotyping in patients with SMI could potentially
individualize treatment, reduce side-effects in slower
metabolizers and increase treatment effects in rapidmetabolizers.
Until now, it remains unclear whether routine CYP2D6
genotyping is efficacious in patients with SMI already
undergoing psychopharmacological treatment and evidence
of clinical utility of CYP2D6 genotyping in patients being
prescribed antipsychotics is lacking (19–21). We hypothesized
that dose adjustment of antipsychotics to the CYP2D6 genotype
and phenotype would be beneficial regarding side-effects,
psychiatric symptoms, quality of life, and/or global functioning.
The aim of the present study was to evaluate the effect of
dose adjustment to the CYP2D6 genotype and phenotype, in
patients with SMI already receiving psychopharmacological
treatment. The dose adjustment group consisted of patients with
a PM, IM, or UM profile using antipsychotics metabolized by
CYP2D6, whereas the control group consisted of patients with
an EM geno-/phenotype. The effect of dose adjustment of the
antipsychotics on psychopathological symptoms, side-effects,
and well-being was evaluated.
1Flockhart DA. P450 Drug Interaction Table (Division of Clinical Pharmacology,
Indiana University). July 12, 2013. Available at: http://medicine.iupui.edu/
clinpharm/ddis/main-table/ (Accessed 2013).
METHODS
Patients
This study was performed on the Caribbean island, Curaçao:
this is one of the western Leeward Antilles in the Caribbean
with about 160,000 inhabitants2. Patients were recruited via the
Klinika Capriles (the psychiatric hospital on the island), the
psychiatric ward of the local prison (FOBA), and the psychiatric
outpatient clinic (Psychiaters Maatschap Antillen).
After being informed about the study procedures, all patients
signed written informed consent. Inclusion criteria were:
Antillean ethnicity (defined in line with the concepts used by
the Central Office of Statistics in the Netherlands, as birth on
the former Netherlands Antilles and birth of at least one parent
on the former Netherlands Antilles); age ≥18 years; use of an
antipsychotic or antidepressant drug; able and written informed
consent. All participants in both groups received a token for 25
Netherlands Antillean Guilder (about US $13) if they completed
the study.
All DNA samples were genotyped July 2012 for CYP2D6
∗1, ∗2, ∗3, ∗4, ∗5, ∗6, ∗7, ∗8, ∗9, ∗10, ∗17, ∗29, ∗41 and gene
duplication in the Erasmus Medical Center (Rotterdam, the
Netherlands) and grouped according to the predicted phenotype
for CYP2D6 as described earlier (22).
Diagnoses, demographic information and information on
psychiatric and somatic medication was derived from the
electronic patient file. The following psychiatric drugs were
considered to have a major dependence on the CYP2D6
enzyme for their elimination: amitriptyline, aripiprazole,
atomoxetine, clomipramine, imipramine, haloperidol,
nortriptyline, paroxetine, pimozide, risperidone, venlafaxine,
and zuclopenthixol1 (9, 10).
Based on the CYP2D6 genotype or phenotype, patients were
selected who were recommended a dose adjustment of their
psychopharmacological medication according to the guideline of
the Royal Dutch Association for the Advancement of Pharmacy
(updated until July 2013). In this guideline, recommendations
were developed for 53 drugs based on a systematic review of the
literature. In CYP2D6 PM, IM, or UM patients, using medication
metabolized by CYP2D6, it is advised to switch to a drug that
is not metabolized by CYP2D6. An alternative is to adjust
the dosage with dose reductions of respectively 25–50% of the
original dose in IMs and PMs (9, 10).
To increase the power of the present study, patients who were
PM or IM based on inhibiting medication were also included in
the dose adjustment group (23).
Patients using strong CYP2D6 inhibitors (bupropion,
cinacalcet, fluoxetine, paroxetine, quinidine) according to
Flockhart’s interaction table, were classified as being PM1
(23, 24).
The selected patients were matched for age, gender and type of
medication with a control group of patients who were CYP2D6
extensive metabolizers.
2Central Bureau of Statistics Curaçao. Available at: http://www.cbs.cw. Accessed
2017.
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All prescribed antipsychotics were calculated to a “defined
daily dose” (DDD) as reported by theWorld Health Organization
(WHO) (25). This is a unit of measurement and defined as the
assumed average maintenance dose per day for a drug used for
its main indication in adults. The total equivalent of the DDD
was calculated for every patient. The study protocol was approved
by the Institutional Review Board of Maastricht University (the
Netherlands) and ethical approval to collect DNA samples was
received according to local policies by the Institutional Review
Board of the Klinika Capriles (Curaçao).
The study was registered in an international trial registry
at http://www.clinicaltrials.gov (NCT02713672). All procedures
were in accordance with the ethical standards of the Declaration
of Helsinki 1975 (as revised in 1983).
Assessments
Each patient underwent a thorough assessment of
psychopathology, subjective experience, extrapyramidal
symptoms, quality of life, global functioning, and metabolic
parameters at baseline (T0) (November–December 2014) and
at 4 months after dose adjustment (T1) (April–June 2015).
Information about drug and alcohol use was registered.
The severity of the patient’s psychopathology was
assessed with the Brief Psychiatric Rating Scale (BPRS)
(26). Extrapyramidal symptoms were assessed with the St.
Hans Rating Scale (SHRS) (27). Akathisia was measured with
the Barnes Rating Scale for drug-induced akathisia (BARS)
(28, 29). Quality of life was assessed with the EQol 5-D (EQ
5-D) (30). Global functioning was assessed with the WHO
Disability Assessment Schedule 2.0 36-item proxy-administered
version (WHODAS 2.0) and was administered with a personal
caregiver (31, 32); scores were recalculated to a standardized
score. In all above-mentioned scales, higher scores indicate more
severe symptoms. Subjective experience was measured with
the Subjective Well-Being Under Neuroleptics Scale (SWN-20)
(33). Scores were recalculated, with higher scores indicating a
higher level of well-being. For patients who were unable to read
Dutch, the questions were translated into Papiamento (a local
language). The investigator, a resident in psychiatry, was trained
by professionals in scoring the SHRS, BARS and the WHODAS
2.0. Patients receiving depot medication were measured the same
number of days after administration of the depot at T0 and at T1.
Secondary outcome measurements were metabolic
parameters (blood pressure, body mass index (BMI), waist
size, cholesterol, HDL, LDL, triglycerides, glucose, HbA1Cl, and
prolactin). Also in 31 of the 60 patients receiving antipsychotics
metabolized by CYP2D6 (dose adjustment group n= 22, control
group n= 9), the plasma levels of antipsychotics were measured.
Procedures
After baseline measurements, another psychiatrist in training
prescribed the dose adjustments. A standard procedure for dose
adjustments was followed. Lowering the dose was done in steps
according to a local protocol3 (34). Tranquilizing medication
3Switching antipsychotics available at: http://wiki.psychiatrienet.nl/index.php/
SwitchAntipsychotics. (Accessed 2014).
with inhibitory activity was replaced by benzodiazepines. By
removing the inhibiting medication, no further dose reduction
was necessary in these patients. Complex cases were discussed
with the research team during a regular meeting and individual
dose adjustment plans were made.
Statistical Analysis
Analyses were performed with IBM SPSS statistics (version
22). Differences between groups were tested with a Chi-square
test for dichotomous variables and an independent t-test for
continuous variables. ANOVA was used to compare means
between the geno-/phenotypes. Non-parametric tests were used
for variables not normally distributed (i.e., SHRS, BARS, EQ 5-
D). Differences at T1 that were present at T0 were corrected for
in an ANCOVA model. The relation between geno-/pheno and
DDD was investigated with Kendall’s tau. All tests were two-
tailed. The significance level was set at p < 0.05. After Bonferroni
correction, the significance level used was p < 0.005 (0.05/11).
To analyse all aspects of deterioration, psychiatric well-being
was evaluated on (one of) three scored items: i.e., deterioration
was defined as a specific report by caregivers or a physician, or a
>5-point increase on the BPRS, or on the WHODAS 2.0.
A post-hoc power analysis showed that a 25% reduction of
the psychiatric symptoms, or a 30% reduction of the symptoms
measured by WHODAS 2.0, or a 75% reduction of the Parkinson
symptoms, results in a power of 80% at a significance level of 0.05.
RESULTS
Baseline Characteristics
The study population consisted of 269 long-term psychiatric
patients, of which 94% was diagnosed with a psychotic disorder.
Other diagnoses weremajor depressive disorder, bipolar disorder,
substance abuse and intellectual disability. No regular drug
or alcohol use was reported in any of the questionnaires. A
quarter of the patients was outpatient. The majority (92%)
was admitted in a long-term treatment facility or institutional
housing at the start of genotyping and had a long treatment
history. Every patient was genotyped 2.5 years before the start of
the intervention, and for at least this period in treatment. Patients
were stable on antipsychotic treatment for at least 2.5 years, three
patients switched once from antipsychotic during this treatment
period.
Genotyping succeeded in 231 participants. Failure of
genotyping was due to the low quality DNA obtained from the
buccal swabs. Frequencies of PMs, IMs, and UMs were similar
to those found in an Antillean population without psychiatric
disease (22); Caucasian populations (22); and in patients using
antipsychotic medication not metabolized by CYP2D6.
In total 111 out of 269 patients were using medication
metabolized by CYP2D6. In total, 153 patients were prescribed
two types of antipsychotics and 24 patients used antidepressant
medication. Because the admitted patients received their
medication from the nurses and two third of the patients
were using depot medication we could account for medication
adherence in 90% of the included patients. Figure 1 presents
an overview of the patient selection and study procedure.
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FIGURE 1 | Study procedure and inclusion of participants. PM, poor metabolizer; IM, intermediate metabolizer; UM, ultrarapid metabolizer; EM, extensive metabolizer.
The medication in the dose adjustment group was haloperidol
(n= 15), risperidone (n= 21), and zuclopenthixol (n= 9).
Out of 41 patients, 16 patients received a dose reduction. The
mean dose reductionwas 0.60DDD, (1.4 DDD in PMs, 0.54DDD
in IMs) which equals a reduction from 5 to 2mg risperidone.
Other patients stopped with their inhibiting medication or
received alternative antipsychotic medication. Table 1 presents
the patient characteristics and the outcome of measurements at
T0 and T1.
Four months after dose adjustment (T1), 81 (94%) patients
were assessed for the follow-up measurements; one patient had
died of cancer, two patients had withdrawn from psychiatric care,
and two patients did not want to participate a second time.
Baseline (T0)
At baseline, no differences were found between the geno-
/phenotype and the mean prescribed dose of antipsychotics as
shown in Figure 2. In the dose adjustment group the mean DDD
was 1.65 (SD 0.83) and in the control group it was 1.92 (SD 0.97)
(Ns). PMs, IMs and UMs were prescribed the same amounts of
psychopharmacological medication as the EMs.
Second, we found no difference in dose-dependent adverse
drug reactions between the normal and extreme metabolizers.
Movement disorders were equally distributed in both groups.
There were no differences in metabolic parameters.
Third, no differences were found between the normal
and extreme metabolizers for psychiatric symptoms, subjective
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TABLE 1 | Clinical characteristics, baseline, and delta scores of the dose adjustment and control group.
T0
dose adjustment group
n = 45
Mean (SD)
T0
control group
n = 41
Mean (SD)
p-value* T1-T0
dose adjustment group
n = 37
Mean (SD)
T1-T0
control group
n = 40 Mean (SD)
p-value*
Male (n) 30 25 0.58
Female (n) 15 16 0.58
Age (years) 52.4 (12.0) 50.3 (10.8) 0.15
Depot medication 30 27 0.59
Outpatient 14 9 0.34
Defined daily dose 1.65 1.92 0.17
BPRS:
24 items (1–7)
1.79 (0.51) 1.66 (0.43) 0.26 −0.26 (0.26) −0.17 (0.27) 0.15
SWN-20:
20 items (1–6)
4.59 (0.95) 4.45 (1.02) 0.59 0.29 (0.66) −0.06 (0.57) 0.04
WHODAS 2.0:
32 items (1–5) (standardized
total score)
32.06 (16.28) 30.40 (16.89) 0.69 5.47 (17.50) 2.93 (10.63) 0.52
EQ 5-D:
5 items (1–3)
1.30 (0.31) 1.31 (0.38) 0.78 −0.07 (0.37) −0.05 (0.24) 0.74
Dyskinesia SHRS:
18 items: (0–6)
0.61 (0.70) 0.78 (0.87) 0.58 0.19 (0.55) 0.045 (0.57) 0.33
Parkinsonism SHRS:
10 items (0–6)
0.97 (1.12) 1.00 (1.33) 0.70 0.47 (0.76) 0.04 (0.72) 0.05
Dystonia SHRS:
2 items (0–6)
0.06 (0.34) 0.27 (1.05) 0.36 0 (0.51) −0.20 (1.00) 0.70
BARS:
3 items (0–3)
0.10 (0.40) 0.37 (0.73) 0.01 0.13 (0.54) −0.26 (0.70) 0.25**
Blood pressure (mmHg) 124/81 (14/10) 125/79 (17/11) 0.60 1.50 (15.48)
/−0.76 (9.72)
−1.89 (15.29)
/−0.76 (9.72)
0.37
BMI 26.6 (6.4) 27.3 (6.7) 0.66 −0.05 (1.51) −0.64 (1.45) 0.12
Cholesterol (mg/dl) 159.8 (37.7) 160.0 (34.4) 0.99 8.8 (22.6) 6.4 (13.6) 0.63
HDL (mg/dl) 45.4 (15.1) 42.4 (10.7) 0.34 3.5 (6.5) 1.2 (6.3) 0.19
LDL (mg/dl) 92.7 (33.8) 92.1 (31.3) 0.94 6.4 (19.8) 8.1 (20.6) 0.76
Triglyceride (mg/dl) 104.5 (41.4) 111.6 (56.7) 0.57 −5.7 (28.4) −6.6 (38.6) 0.93
Prolactin (ng/ml) 37.3 (62.1) 20.2 (14.4) 0.22 −13.0 (37.5) 2.6 (10.0) 0.11
Fasting glucose (mg/dl) 112.0 (25.1) 103.2 (32.0) 0.24 −4.1 (14.8) −4.2 (17.4) 0.98
HbA1c % 4.5 (1.5) 5.4 (1.5) 0.33 −0.1 (0.0) −0.08 (0.43) 0.95
*Significance level after Bonferroni correction p< 0.005. **ANCOVA test corrected for differences at T0 that were present at T1; BPRS, Brief Psychiatric Rating Scale; SWN-20, Subjective
Well-being Under Neuroleptics; WHODAS, World Health Organization Disability Assessment Schedule; SHRS, St. Hans Rating Scale; BARS, Barnes Rating Scale for drug-induced
akathisia.
well-being and quality of life. There were no differences in
psychiatric symptoms as measured by subscales of the BPRS.
Because only 13 of the patients worked, the four items of the
WHODAS 2.0 concerning work were omitted. Patients with a
PM genotype or phenotype scored higher on the WHODAS 2.0
than the IMs (PM 41.5, IM 26.6, EM 29.1, UM 34.0) (p = 0.007);
however, this difference was not significant after Bonferroni
correction (p= 0.005).
Fourth, no significant differences were found between the
dose adjustment and the control group in mean therapeutic
drug plasma levels of antipsychotics metabolized by CYP2D6
(analyzed with theMann-WhitneyU-test). Themean therapeutic
plasma levels at T0 of respectively the dose adjustment and the
control group were for haloperidol 0.0015 mg/l (SD 0.0013)
(n = 4) and 0.0023 mg/l (SD 0.0006) (n = 3) (p = 0.35);
risperidone 0.0173 mg/l (SD 0.0164) (n = 9) and 0.0073 mg/l
(SD 0.0081) (n = 3) (p = 0.34); zuclopenthixol 0.0143 mg/l (SD
0.0167) (n = 9) and 0.0160 mg/l (SD 0.0227) (n = 2) (p = 0.91).
In the dose adjustment and control group there was a linear
incremental relationship between dose and plasma level (data not
shown).
Separate analyses were performed with the exclusion of the 12
patients with a PM profile who were selected due to inhibiting
medication (data not shown); however, this exclusion had no
effect on the results. There were no differences in outcomes
between males and females (data not shown).
Effect of Dose Adjustment
No significant effect of dose adjustment was found on psychiatric
symptoms, quality of life, or global functioning. Of the 41 patients
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FIGURE 2 | Prescribed dose of antipsychotics in DDD per CYP2D6 geno-/phenotype group at baseline. DDD, defined daily dose; PM, poor metabolizer; IM,
intermediate metabolizer; UM, ultrarapid metabolizer; Error Bars, ±1 SD.
receiving dose adjustment, six returned to the original dose of
the antipsychotics because of deterioration after dose adjustment.
Deterioration of psychiatric symptoms resulted in two clinical
admissions of outpatients of the dose adjustment group, whereas
no admissions were reported in the control group; this difference
was not significant.
There was no significant difference in deterioration in
psychiatric symptoms between the two groups. In the dose
adjustment group, 16 patients (39%) showed a decline in one
of three aspects (defining deterioration) compared with 14
patients (34%) in the control group. In patients who deteriorated,
the mean prescribed dose of antipsychotics (in DDD) after
dose adjustment was equivalent to the DDD in patients who
remained stable (data not shown). Table 1 shows the mean
changes in scores after dose adjustment (T1-T0). There were no
differences in outcomes between males and females (data not
shown). Table 2 shows the individual therapeutic plasma levels
of antipsychotics (mg/l) metabolized by CYP2D6 of the nine
patients in the dose adjustment group who participated in the
measurements at T0 and T1.
Effect of Dose Adjustment on Side-Effects
and Well-being
Dose adjustment did not result in a significant improvement
of parkinsonism, dyskinesia, dystonia, or akathisia. There was a
slight improvement (6%) in well-being as measured by the SWN-
20. However, this is not considered a clinical relevant finding and
is not significant after Bonferroni correction.
Effect of Dose Adjustment on Metabolic
Parameters
Table 1 shows changes in metabolic parameters from baseline
until after dose adjustment; no significant differences were found
between the two groups.
DISCUSSION
This study rejected the hypothesis that patients with SMI on
antipsychotic treatment in a clinical setting benefit from dose
adjustment based on the CYP2D6 genotype or phenotype.
Importantly, at baseline, no differences were found in the severity
of side-effects or global/psychiatric functioning between the dose
adjustment group (with PM, IM, and UM) and control group
(with EM). There was no effect of dose adjustment on these
parameters.
We expected before we started the study that during years
of treatment, clinicians would have optimized dosages to the
geno-/phenotype based on side-effects or effectiveness of the
drugs used. However at baseline, the CYP2D6 PMs, IMs, and
UMs used the same amount of antipsychotics as the EMs.
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TABLE 2 | Therapeutic plasma levels of antipsychotics (mg/l) metabolized by CYP2D6 of the nine patients in the dose adjustment group measured at T0 and T1.
Dose
adjustment (%)
Plasma level
change (%)
T0 T1 T1–T0
H R Z H R Z H R Z
Participant 1 −25 0.0120 Undetectable*
Participant 2 −25 −54 0.0130 0.0060 −0.0070
Participant 3 −25 −44 0.0250 0.0140 −0.0110
Participant 4 −25 Undetectable* 0.0050
Participant 5 STOP 0.0350 Undetectable*
Participant 6 STOP −65 0.0260 0.0090 −0.0170
Participant 7 STOP 0 0.0010 0.0010 0.0000
Participant 8 STOP Undetectable* Undetectable*
Participant 9 STOP Undetectable* 0.0110
*All patients were using depot medication and medication adherence was guaranteed, therefore a lab result of 0 was interpreted as undetectable. H, Haloperidol; R, Risperidone; Z,
Zuclopenthixol; STOP, stopped with inhibiting medication.
This finding motivated us to find out if dose adjustment could
improve the clinical picture. A possible explanation for the
absence of an effect, which could also explain the deterioration
of some patients, is that long-term use of antipsychotics induces
structural brain changes and the brain adapts to the changed
dopamine levels (35). It is suggested that antipsychotics play a
role in the progressive reduction of brain size and enlargement
of ventricular spaces in patients with schizophrenia, which is
associated with involuntary movement disorders (36, 37). Studies
show that patients with long-term antipsychotic treatment have
a threefold increase in loss of dopamine terminals in the
substantia nigra (15% per decade vs. 5% in healthy controls)
which is suggested to play a role in persistent parkinsonism
and tardive dyskinesia (38). Additionally, it is reported that only
3% of patients discontinuing movement disorder-causing agents,
resolved spontaneously from tardive syndromes and a reduction
of the dosage of antipsychotics did not decrease the severity of
parkinsonism (39, 40). It could be that in this clinical population,
a dose adjustment to CYP2D6 might have had an effect in an
earlier disease stadium but after years of treatment has come too
late.
Another possible explanation for these findings is that in
both our study groups, the baseline dosage of antipsychotics
may have been so high (average DDD 1.65) that D2 receptor
occupancy exceeded the optimal window for subjective well-
being and to forestall extrapyramidal side-effects (41, 42). This
could explain why we found no differences in the prevalence of
movement disorders and subjective well-being between the dose
adjustment group and control group. However, no improvements
in extrapyramidal and psychiatric symptoms were found in our
patients using lower dosages of antipsychotics (DDD 1.0, after
reduction DDD 0.5).
Lastly, the role of the CYP2D6 genotype as a major factor in
themetabolization of antipsychotics might be overestimated. The
present study supports this hypothesis by showing no differences
in plasma levels of drugs in the different phenotypes. Another
clinical study showed, that a proportion of healthy individuals
with a PM genotype are phenotypically EMs as measured by
CEIBA metabolization (43).
In clinical practice, in patients with SMI, common factors as
co-morbidities, inflammation, age, smoking, and drug/alcohol
use, could cause conversion of genotypic PMs into phenotypic
EMs and the other way around (44–49). This undetected
phenomenon, named phenoconversion, might explain the
negative outcome effects in the present study.
Although a small group of patients (n = 14) remained stable
with lower dosages of antipsychotics, no patients improved in
clinical symptoms. This relatively minor saving in direct costs,
did not weigh up to the costs of genotyping a large group of
patients (n= 269).
Strengths and Limitations
This is the first study which prospectively investigated the clinical
utility of dose adjustment to the CYP2D6 genotype or phenotype
in patients on antipsychoticmedication (20). The representativity
was high as we were able to approach all psychiatric patients, with
a homogenous African-Caribbean background in a restricted
area, i.e., we included all three psychiatric institutes on the
island of Curaçao. When including patients, no selection was
made regarding the type of psychiatric care, medication, presence
of side-effects or treatment response. This has resulted in a
heterogeneous group of patients, representative for a general
clinical population. It allowed us to analyse the effects of
genotyping and dose adjustment in a clinical setting and has led
to results with practical clinical value. We have no treatment
history of the patients more than 2.5 years before the start of the
dose adjustment but we know from clinical practice that patients
with SMI make several switches in antipsychotics during the
course of their illness and treatment. Earlier studies, in a larger
population from this same clinic (40, 50) show this is also true
for this population.
Although a large cohort of 269 psychiatric patients was
genotyped, only a small number of patients (45) had an extreme
geno-/phenotype and used medication metabolized by CYP2D6;
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therefore, a randomized controlled trial design was not possible.
A control group was used to investigate differences between
normal and extreme metabolizers before dose adjustment and
to monitor possible effects from time. Furthermore, the design
of the study, with a rater who was blinded to whether a patient
was in the dose adjustment group or the control group, reduced
possible expectation bias.
Ideally we would have analyzed the effect of dose adjustment
in patients using only one type of antipsychotic medication,
due to the small numbers of extreme metabolizers this was
not possible. Because all the investigated antipsychotics are
metabolized by CYP2D6 as reported in the Flockhart table, it is
very unlikely that this accounted for the absence of an effect.
At last, the Food and Drugs Administration provides a list
of strong and weak inhibitors and, by inclusion of patients with
a PM/IM phenotype based on interacting medication, greatly
improved the prediction of the correct phenotype and has
increased the power of the study (23, 24). Post-hoc power analysis
showed that the number of included patients was high enough
to demonstrate clinical relevant results. Moreover, not one out
of 45 patients showed an evident improvement in side-effects,
psychiatric symptoms or functioning after dose adjustment and
six patients returned to their original doses, due to deterioration
of psychiatric symptoms. This supports the conclusion that
adjustment of the dose based on the CYP2D6 geno-/phenotype
had no effect.
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